Table I.
Clinical characteristics of patients with neurogenic orthostatic hypotension (n=10)
| Sex (M/F) | 63/41 |
| Age (years) (mean±SD) | 71±10 |
| MSA | 45 (43.2%) |
| PD | 43 (41.3%) |
| PAF | 9 (8.6%) |
| Other | 7 (6.7%) |
| Follow-up (months) (median) | 52.8 |
| Comorbidities | |
| Hypertension | 32 (30.7%) |
| Begnin prostate hypertrophy | 17 (16.3%) |
| Gastroenterological | 14 (13.4%) |
| Psychiatric | 14 (13.4%) |
| Cerebrovascular | 13 (12.5%) |
| Cancer | 12 (11.5%) |
| Respiratory | 11 (11.5%) |
| Cardiac | 10 (9.6%) |
| Endocrinological | 6 (5.7%) |
| Peripheral vascular disease | 5 (4.8%) |
| Chronic renal failure | 5 (4.8%) |
| Haematological | 3 (2.8%) |
| Neurological | 2 (1.9%) |
| Dermatological | 2 (1.9%) |
| Orthopaedic | 1 (0.9%) |
| Osteoporosis | 1 (0.9%) |
| Therapies | |
| Midodrine | 77 (74.0%) |
| Fludrocortisone | 68 (65.3%) |
| Octreotide | 14 (13.4%) |
| Dihydroergotamine | 6 (5.7%) |
| Acarbose | 3 (2.8%) |
| ACE-inhibitors | 31 (29.8%) |
| Nitrates | 18 (17.3%) |
| Complications | |
| Heart failure | 22 (21.2%) |
| Atrial fibrillation | 5 (4.8%) |
Abbreviations: PAF=pure autonomic failure; MSA=multiple system atrophy; PD=Parkinson’s disease with autonomic neuropathy; other= remaining AN subtypes.